Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

Arvinas (ARVN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Mergers and acquisitions grabbed the spotlight in the biotech sector once again this week after Bristol Myers Squibb BMY ...

Arvinas (ARVN) stock faces a downgrade after underwhelming trial data for breast cancer drug vepdegestrant developed with ...

BMO Capital analyst Etzer Darout lowered the firm’s price target on Arvinas (ARVN) to $20 from $82 and keeps an Outperform rating on the ...

BofA lowered the firm’s price target on Arvinas (ARVN) to $28 from $54 and keeps a Buy rating on the shares after the Phase 3 VERITAC-2 trial ...

Guggenheim analyst Michael Schmidt maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report) yesterday and set a price target of $57.00. The company’s shares ...

Arvinas & Pfizer announce positive topline results from phase 3 VERITAC-2 clinical trial: New Haven, Connecticut Wednesday, March 12, 2025, 10:00 Hrs [IST] Arvinas, Inc., a clinic ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...

Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.

Pfizer (NYSE:PFE) stock and Arvinas (NASDAQ:ARVN) stock slip in reaction to mixed Phase 3 data for their breast cancer drug ...

VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival - - ...